By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...